ADAP - Adaptimmune Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5366.54M
Enterprise Value 3222.14M
Trailing P/E N/A
Forward P/E 1-3.24
PEG Ratio (5 yr expected) 1-3.02
Price/Sales (ttm)7.14
Price/Book (mrq)1.67
Enterprise Value/Revenue 34.33
Enterprise Value/EBITDA 6-2.79

Trading Information

Stock Price History

Beta (3Y Monthly) 1.82
52-Week Change 3-68.52%
S&P500 52-Week Change 37.70%
52 Week High 314.5400
52 Week Low 33.2000
50-Day Moving Average 33.6445
200-Day Moving Average 34.3322

Share Statistics

Avg Vol (3 month) 3293.25k
Avg Vol (10 day) 3175.6k
Shares Outstanding 5104.72M
Float 47.71M
% Held by Insiders 10.22%
% Held by Institutions 173.00%
Shares Short (Jun 28, 2019) 43.66M
Short Ratio (Jun 28, 2019) 415.12
Short % of Float (Jun 28, 2019) 4N/A
Short % of Shares Outstanding (Jun 28, 2019) 43.49%
Shares Short (prior month May 31, 2019) 43.93M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin -198.50%
Operating Margin (ttm)-170.37%

Management Effectiveness

Return on Assets (ttm)-21.11%
Return on Equity (ttm)-49.57%

Income Statement

Revenue (ttm)51.31M
Revenue Per Share (ttm)0.51
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-38.76M
EBITDA -79.5M
Net Income Avi to Common (ttm)-101.85M
Diluted EPS (ttm)-1.0170
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)168.16M
Total Cash Per Share (mrq)1.61
Total Debt (mrq)29M
Total Debt/Equity (mrq)13.20
Current Ratio (mrq)8.55
Book Value Per Share (mrq)2.10

Cash Flow Statement

Operating Cash Flow (ttm)-93.31M
Levered Free Cash Flow (ttm)-63.97M